OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Untangling the threads of immunotherapy research	535
Outcompeting neighbors for intestinal cancer initiation	342
Gut decisions in CAR T cell therapy	339
A low-coverage liquid biopsy for lung cancer	301
Alzheimer’s drug turns macrophages against cancer	296
PARP11 interfer(on)es with CAR T cell efficacy	274
Enhancing childhood cancer targetability	259
Shooting for multiplexed pathology with Orion	254
An oncolytic circular RNA therapy	252
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	233
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	230
A macrophage-activated abscopal effect	228
Breaking frontiers with multidisciplinary cancer research	197
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	185
MALAT1 protects dormant tumor cells from immune elimination	185
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	178
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	175
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	167
Considering molecular alterations as pan-cancer tissue-agnostic targets	165
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	159
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	158
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	148
The cGAS–STING pathway and cancer	147
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	140
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	140

Expanding the options for KRAS inhibition	134
The importance of being generous	129
Reflecting on the golden age of cancer research	125
DePICting T cell–APC crosstalk in cancer	123
Beating cancer one carbon at a time	121
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	120
Bone marrow progenitor-like cells against leukemia cure	113
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	113
Shaping the microenvironment in peritoneal metastases	106
Palmitate oxidation drives a pro-metastatic post-translational modification	106
Determinants of resistance and response to melanoma therapy	103
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	101
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	100
Impact of context-dependent autophagy states on tumor progression	100
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	100
Engineering-enhanced CAR T cells for improved cancer therapy	100
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	99
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	98
The labors of referees	98
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	97
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	94
LAG-3 and PD-1 blockade raises the bar for melanoma	92
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	92
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	89
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	88
Thriving in diverse ecosystems	86
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	84
Inflammation meets translation in AML	84
A quick guide for clinical oncology	84
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	83
Sarcoma ecotypes determine immunotherapy benefit	82
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	81
A comeback for checkpoint inhibition in multiple myeloma	81
Antibody avidity meets multiple myeloma	81
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	79
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	77
Cycling back to folate metabolism in cancer	77
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	77
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	75
Multimodal data integration improves immunotherapy response prediction	75
Radioligand cancer therapy comes to the fore	74
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	73
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
How AI agents will change cancer research and oncology	73
Immunotargeting of a recurrent AML-specific neoantigen	72
Bispecific antibodies seek out colon cancer stem cells	72
Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy	71
A Wnt twist in FTO’s role in cancer progression	71
Dual inhibition of EGFR and PI3K with a single drug	71